<DOC>
	<DOCNO>NCT01815424</DOCNO>
	<brief_summary>The primary objective study compare efficacy CP-690,550 ( 5 mg BID 10 mg BID ) versus placebo reduction severity plaque psoriasis 16 week treatment Asian subject moderate severe chronic plaque psoriasis candidate systemic therapy phototherapy .</brief_summary>
	<brief_title>A Study Evaluating The Efficacy And Safety Of CP-690,550 In Asian Subjects With Moderate To Severe Plaque Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Tofacitinib</mesh_term>
	<criteria>Have diagnosis plaquetype psoriasis ( psoriasis vulgaris ) least 12 month prior first screening procedure . Have PASI score 12 great AND PGA score 3 ( `` moderate '' ) 4 ( `` severe '' ) Baseline ( Day 1 ) . Considered dermatologist investigator candidate systemic therapy phototherapy psoriasis ( either na√Øve history previous treatment ) . Currently nonplaque form psoriasis , eg , erythrodermic , guttate , pustular psoriasis , exception nail psoriasis allow . Have current drug induce psoriasis , eg , new onset psoriasis exacerbation psoriasis beta blocker , calcium channel blocker , antimalarial drug lithium . Subjects discontinue systemic therapy and/or topical therapy treatment psoriasis discontinue phototherapy ( UVB PUVA ) study exclude .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Tofacitinib</keyword>
	<keyword>CP-690</keyword>
	<keyword>550</keyword>
	<keyword>Xeljanz</keyword>
	<keyword>Jak-Inhibitor</keyword>
	<keyword>Oral Treatment</keyword>
	<keyword>Psoriasis vulgaris</keyword>
	<keyword>Pruritus</keyword>
	<keyword>Itch</keyword>
	<keyword>DLQI</keyword>
	<keyword>moderate</keyword>
	<keyword>severe</keyword>
	<keyword>chronic</keyword>
	<keyword>plaque psoriasis</keyword>
</DOC>